Download Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance Ebook PDF

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance
A Book

by Andrew Freywald,Franco Vizeacoumar

  • Publisher : Academic Press
  • Release : 2020-12-04
  • Pages : 308
  • ISBN : 0128213116
  • Language : En, Es, Fr & De
GET BOOK

Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance, Volume 12, discusses new approaches that are being undertaken to counteract tumor plasticity, understand and tackle the interactions with the microenvironment, and disrupt the rewiring of malignant cells or bypass biological mechanism of resistance by using targeted radionuclide therapies. This book provides a unique opportunity to the reader to understand the fundamental causes of drug resistance and how different approaches are applied. It is a one-stop-shop to understand why it is so difficult to treat cancer, and why only a very few patients respond to therapy and a significant portion develop resistance. Despite a rapid development of more effective anti-cancer drugs and combination therapies, cancer remains the leading cause of lethality in the developed world. The main reason for this is the ability of heterogeneous subpopulations of tumor cells interacting with constantly evolving tumor microenvironment to resist elimination and eventually, trigger cancer relapse. In this book, experts review current concepts explaining molecular and biological mechanisms of cancer drug resistance and discussing advancing approaches for overcoming these therapeutic challenges. Provides the most updated knowledge on the mechanisms of cancer drug resistance and the emerging therapeutic approaches reviewed by experts in the field Brings detailed analyses of most important recently reported developments related to drug resistance and their relevance to overcoming it in cancer patients Discusses in-depth molecular mechanisms and novel concepts of cancer resistance to conventional and advanced therapies

Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance
A Book

by Goli Samimi,Christina Annunziata

  • Publisher : Academic Press
  • Release : 2020-11-19
  • Pages : 188
  • ISBN : 0128198419
  • Language : En, Es, Fr & De
GET BOOK

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Therapeutic Strategies to Overcome ALK Resistance in Cancer

Therapeutic Strategies to Overcome ALK Resistance in Cancer
A Book

by Luc Friboulet

  • Publisher : Academic Press
  • Release : 2021-01-18
  • Pages : 216
  • ISBN : 0128217790
  • Language : En, Es, Fr & De
GET BOOK

Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops. This book discusses topics such as structure and function of ALK, ALK rearranged lung cancer, resistance mechanisms to ALK TKI tumors, and novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL. Additionally, it encompasses information on drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma and future perspectives in the field. This book is a valuable resource for cancer researchers, clinicians and several members of biomedical field who need to understand more about how to fight ALK resistance in cancer treatment. Explains the biology of ALK RTK, focusing on its tissue expression, structure and functionality Presents an overview of current treatments and the benefits of ALK TKI in lung and other cancer types, such as ALCL, neuroblastoma and inflammatory myofibroblastic tumor Encompasses information on systemic treatments other than TKI, including chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC

pH-Interfering Agents as Chemosensitizers in Cancer Therapy

pH-Interfering Agents as Chemosensitizers in Cancer Therapy
A Book

by Claudiu Supuran,Simone Carradori

  • Publisher : Academic Press
  • Release : 2020-09-15
  • Pages : 228
  • ISBN : 0128209283
  • Language : En, Es, Fr & De
GET BOOK

pH Interfering Agents as Chemosensitizers In Cancer Therapy, Volume Thirteen, provides a detailed overview of the chemosensitizers for the treatment of cancer spanning from biochemical and structural features to pharmacology and drug-design, including technological applications. The book is structured with innovative outlines and a distinction between experimental and clinical results. The continuous discovery and assessment of the role played by old/new synthetic drugs, natural compounds and technological applications has led to the urgent need of classification in terms of biological activity, mechanism of action, clinical outcomes, cancer cell lines sensible to the treatment, and potentialities to better orient research in this field. Moreover, all the aspects relevant for medicinal chemistry (drug design, structure-activity relationships, permeability data, cytotoxicity, appropriate statistical procedures, and molecular modeling studies) are strictly considered. Presents a broad view of the topic according to a medicinal chemistry-based approach beyond syntheses and biological assays, focusing on SAR studies, chemoinformatic, drug targeting and molecular modeling Explains the mechanism of action of the chemosensitizers by means of schemes and figures to facilitate comprehension Discusses novel targets to explore new possibilities that enhance research in the field

Kinase Drug Discovery

Kinase Drug Discovery
Modern Approaches

by Richard A. Ward,Frederick W. Goldberg

  • Publisher : Royal Society of Chemistry
  • Release : 2018-10-10
  • Pages : 414
  • ISBN : 1788010833
  • Language : En, Es, Fr & De
GET BOOK

Kinase inhibition remains an area of significant interest, and growing importance, across academia and the pharmaceutical industry. There are now many marketed drugs that target kinases and a significant number of compounds are currently in various stages of clinical development. This book is a forward-looking analysis of a number of key areas for kinase inhibition in the coming years.

Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders

Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders
A Book

by Lucia Morbidelli,Benjamin Bonavida

  • Publisher : Academic Press
  • Release : 2019-02-09
  • Pages : 372
  • ISBN : 0128172797
  • Language : En, Es, Fr & De
GET BOOK

Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders presents updated reviews on the chemistry, signaling, pre-clinical and clinical activities on the role of nitric oxide donors/inhibitors used alone and in combination with other therapeutic agents for the treatment of a variety of diseases. This book examines various studies related to the application of novel therapeutic NO (donors/inhibitors) compounds in the treatment of various cancers. These studies have been shown to exert significant therapeutic activities against various cancers and various inflammatory diseases such as rheumatoid arthritis, Crohn’s disease, allergies, and asthma, where no current effective therapies exist. Pathologies based on functional and structural vascular alterations are also taken into consideration. Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students. Provides readers with a clear overview of the recent findings and references as well as summaries, significant molecular pathways, and conclusions Discusses new ideas proposed and makes suggestions for further investigations that will advance the field Presents introductory and summary information on the contributions of the field, all the findings of the studies discussed, and projects future goals for research

National Conference on the Care of the Child with Cancer

National Conference on the Care of the Child with Cancer
The Sheraton-Boston Hotel, Boston, Massachusetts, September 11-13, 1978

by Anonim

  • Publisher : Unknown Publisher
  • Release : 1979
  • Pages : 200
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Ovarian Cancers

Ovarian Cancers
Evolving Paradigms in Research and Care

by National Academies of Sciences, Engineering, and Medicine,Institute of Medicine,Board on Health Care Services,Committee on the State of the Science in Ovarian Cancer Research

  • Publisher : National Academies Press
  • Release : 2016-05-25
  • Pages : 396
  • ISBN : 0309380464
  • Language : En, Es, Fr & De
GET BOOK

In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.

Nanobiomaterials in Cancer Therapy

Nanobiomaterials in Cancer Therapy
Applications of Nanobiomaterials

by Alexandru Grumezescu

  • Publisher : William Andrew
  • Release : 2016-03-22
  • Pages : 588
  • ISBN : 032342886X
  • Language : En, Es, Fr & De
GET BOOK

Nanobiomaterials in Cancer Therapy presents the major applications of nanobiomaterials in oncology, offering an up-to-date overview of the latest research in this field. Utilizing nanobiomaterials, novel therapeutic approaches enable significant improvements in drug-loading capacity, formulation stability and drug efficiency. In this book, leading researchers from around the world share their expertise and unique insights. The book covers the fabrication methods of platforms for multimodal and combinatorial therapeutic options, along with simultaneous and real-time cancer imaging, and innovative approaches for oncology by passive or active pathways of multifunctional nanocarriers. The work also classifies and discusses engineered nanobiosystems for cancer therapy, prevention, and low cancer recurrence or relapse. This book will be of interest to postdoctoral researchers, professors and students engaged in the fields of materials science, biotechnology and applied chemistry. It will also be highly valuable to those working in industry, including pharmaceutics and biotechnology companies, medical researchers, biomedical engineers and advanced clinicians. A comprehensive resource for researchers, practitioners and students working in biomedical, biotechnological and engineering fields A valuable guide to recent scientific progress and the latest application methods Discusses novel opportunities and ideas for developing or improving technologies in nanomedicine and nanobiology

Challenges to Tackling Antimicrobial Resistance

Challenges to Tackling Antimicrobial Resistance
Economic and Policy Responses

by Michael Anderson,Michele Cecchini,Elias Mossialos

  • Publisher : Cambridge University Press
  • Release : 2020-04-30
  • Pages : 240
  • ISBN : 1108799450
  • Language : En, Es, Fr & De
GET BOOK

An accessible overview of the challenges in tackling AMR and the economic and policy responses of the 'One Health' approach. It will appeal to policy-makers seeking to strengthen national and local polices tackling AMR, as well as students and academics who want an overview of the latest scientific evidence regarding effective AMR policies.

Nanotheranostics for Cancer Applications

Nanotheranostics for Cancer Applications
A Book

by Prakash Rai,Stephanie A. Morris

  • Publisher : Springer
  • Release : 2018-11-12
  • Pages : 480
  • ISBN : 3030017753
  • Language : En, Es, Fr & De
GET BOOK

This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotely triggered drug delivery systems to limit cytotoxicity in the diseased area. This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics.

Cancer Drug Design and Discovery

Cancer Drug Design and Discovery
A Book

by Stephen Neidle

  • Publisher : Elsevier
  • Release : 2011-04-28
  • Pages : 496
  • ISBN : 9780080554952
  • Language : En, Es, Fr & De
GET BOOK

The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories

Biomedical Chemistry

Biomedical Chemistry
Current Trends and Developments

by Nuno Vale

  • Publisher : Walter de Gruyter GmbH & Co KG
  • Release : 2015-01-01
  • Pages : 361
  • ISBN : 3110468751
  • Language : En, Es, Fr & De
GET BOOK

Biomedical Chemistry provides readers with an understanding of how fundamental chemical concepts are used to combat some diseases. The authors explain the interdisciplinary relationship of chemistry with biology, physics, pharmacy and medicine. The results of chemical research can be applied to understand chemical processes in cells and in the body, and new methods for drug transportation. Also, basic chemical ideas and determination of disease etiology are approached by developing techniques to ensure optimum interaction between drugs and human cells. This Book is an excellent resource for students and researchers in health-related fields with frontier topics in medicinal and pharmaceutical chemistry, organic chemistry and biochemistry.

The Drug Development Paradigm in Oncology

The Drug Development Paradigm in Oncology
Proceedings of a Workshop

by National Academies of Sciences, Engineering, and Medicine,Health and Medicine Division,Board on Health Care Services,National Cancer Policy Forum

  • Publisher : National Academies Press
  • Release : 2018-03-12
  • Pages : 144
  • ISBN : 0309457947
  • Language : En, Es, Fr & De
GET BOOK

Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of effortsâ€"by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)â€"to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities. To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.

Targeted Therapies

Targeted Therapies
Mechanisms of Resistance

by Daniel Gioeli

  • Publisher : Springer Science & Business Media
  • Release : 2011-06-02
  • Pages : 202
  • ISBN : 9781607614784
  • Language : En, Es, Fr & De
GET BOOK

This volume explores the mechanisms of resistance to targeted therapeutics. The focus is on the cancer cell signaling network, although other mechanisms of resistance including target mutation, and new areas of study such as cancer stem cells are included. Targeted Therapies: Mechanisms of Resistance highlights examples of changes in the signaling network in response to inhibition of a signaling event and underscores the importance in having a mechanistic understanding of the signaling network in cancer for developing effective targeted cancer therapies. Moreover, cutting edge tools to analyze the cell signaling network will be discussed. This includes the leading edge of techniques as well as computational biology and systems theory. This volume provides the reader with both an overview as well as a detailed perspective on the mechanisms of resistance to targeted therapeutics and will be of great value to the oncologist, the physician-scientist treating patients and the translational scientist working on any aspect of targeted therapeutics.

Drug Resistance in the Treatment of Cancer

Drug Resistance in the Treatment of Cancer
A Book

by Herbert M. Pinedo,Giuseppe Giaccone

  • Publisher : Cambridge University Press
  • Release : 2007-01-18
  • Pages : 340
  • ISBN : 9780521030748
  • Language : En, Es, Fr & De
GET BOOK

International authorities review the mechanisms and clinical implications of drug resistance in cancer.

Precision Medicine for Investigators, Practitioners and Providers

Precision Medicine for Investigators, Practitioners and Providers
A Book

by Joel Faintuch,Salomao Faintuch

  • Publisher : Academic Press
  • Release : 2019-11-16
  • Pages : 640
  • ISBN : 0128191791
  • Language : En, Es, Fr & De
GET BOOK

Precision Medicine for Investigators, Practitioners and Providers addresses the needs of investigators by covering the topic as an umbrella concept, from new drug trials to wearable diagnostic devices, and from pediatrics to psychiatry in a manner that is up-to-date and authoritative. Sections include broad coverage of concerning disease groups and ancillary information about techniques, resources and consequences. Moreover, each chapter follows a structured blueprint, so that multiple, essential items are not overlooked. Instead of simply concentrating on a limited number of extensive and pedantic coverages, scholarly diagrams are also included. Provides a three-pronged approach to precision medicine that is focused on investigators, practitioners and healthcare providers Covers disease groups and ancillary information about techniques, resources and consequences Follows a structured blueprint, ensuring essential chapters items are not overlooked

Globalization, Biosecurity, and the Future of the Life Sciences

Globalization, Biosecurity, and the Future of the Life Sciences
A Book

by National Research Council,Institute of Medicine,Board on Global Health,Policy and Global Affairs,Development, Security, and Cooperation,Committee on Advances in Technology and the Prevention of Their Application to Next Generation Biowarfare Threats

  • Publisher : National Academies Press
  • Release : 2006-06-07
  • Pages : 316
  • ISBN : 9780309164757
  • Language : En, Es, Fr & De
GET BOOK

Biomedical advances have made it possible to identify and manipulate features of living organisms in useful ways--leading to improvements in public health, agriculture, and other areas. The globalization of scientific and technical expertise also means that many scientists and other individuals around the world are generating breakthroughs in the life sciences and related technologies. The risks posed by bioterrorism and the proliferation of biological weapons capabilities have increased concern about how the rapid advances in genetic engineering and biotechnology could enable the production of biological weapons with unique and unpredictable characteristics. Globalization, Biosecurity, and the Future of Life Sciences examines current trends and future objectives of research in public health, life sciences, and biomedical science that contain applications relevant to developments in biological weapons 5 to 10 years into the future and ways to anticipate, identify, and mitigate these dangers.

Multidrug Resistance in Cancer: Pharmacological Strategies from Basic Research to Clinical Issues

 Multidrug Resistance in Cancer: Pharmacological Strategies from Basic Research to Clinical Issues

by Stefania Nobili,Enrico Mini,Chiara Riganti

  • Publisher : Unknown Publisher
  • Release : 2015-07-06
  • Pages : 329
  • ISBN : 2889196151
  • Language : En, Es, Fr & De
GET BOOK

More than 40 years ago, the observation that doxorubicin-resistant tumor cells were cross-resistant to several structurally different anticancer agents was the first step in the discovery of P-glycoprotein (P-gp). P-gp belongs to the superfamily of ATP-binding cassette (ABC) transporters;its overexpression has become a therapeutic target for overcoming multidrug resistance in tumors. However, P-gp is also expressed in cells of normal tissues where it plays a physiological role, by protecting them from the toxic effects of xenobiotics. Also, ABCB1 gene polymorphisms may influence the response to anticancer drugs substrate of P-gp. Several strategies to overcome P-gp tumor drug resistance have been suggested. P-gp 'circumvention’ is the most explored and is based on the coadministration of anticancer agents and pump inhibitors (P-gp modulators). Despite the positive findings obtained in preclinical studies, results of clinical trials are not yet successful and clinical research is still ongoing. Other investigational approaches have been studied (e.g. P-gp targeting antibodies, use of antisense strategies or transcriptional regulators targeting ABCB1 gene expression) but their use is still circumscribed to the preclinical setting. A further approach is represented by the encapsulation of P-gp substrate anticancer drugs into liposomes or nanoparticles. This strategy has shown higher efficacy in tumor previously treated with the free drug. The reasons explaining the increased efficacy of liposomal/nanoparticle-based drugs in Pgp-overexpressing tumors include the coating with specific surfactants, the composition changes in the plasma membrane microdomains where P-gp is embedded, the direct impairment of P-gp catalytic mechanisms exerted by specific component of the liposomal shell, but are not yet fully understood. A second strategy to overcome P-gp tumor drug resistance is represented by exploiting the P-gp presence. Actually, P-gp-overexpressing cells show increased sensitivity (collateral sensitivity) to some drugs (e.g. verapamil, narcotic analgesics) and to some investigational compounds (e.g. NSC73306). P-gp-overexpressing cell are hypersensitive to reactive oxygen species, to agents perturbing the energetic metabolic pathways, changing the membrane compositions, reducing the efflux of endogenous toxic catabolites. However, the mechanisms explaining collateral sensitivity have not been fully elucidated. Another approach to exploit P-gp is represented by ABCB1 gene transfer to transform bone marrow progenitor cells into a drug resistant state which may allow conventional or higher doses of anticancer drug substrates of P-gp to be administered safely after transplantation. More recently the development and introduction in the clinics of anticancer drugs which are not substrates of P-gp (e.g. new microtubule modulators, topoisomerase inhibitors) has provided a new and promising strategy to overcome P-gp tumor drug resistance (P-gp 'evasion'). This ‘research topic’ issue aims at exploding the above mentioned matters, in particular by: -retracing the history of the first researches on P-gp - describing the physiological role of P-gp - describing the molecular basis, structural features and mechanism of action of P-gp - describing diagnostic laboratory methods useful to determine the expression of P-gp and its transporter function - describing strategies to overcome tumor drug resistance due to P-gp and other ABC transporters - indicating novel approaches to overcome P-gp multidrug resistance, ranging from basic research studies to pre-clinical/clinical studies.

The Annals of Pharmacotherapy

The Annals of Pharmacotherapy
A Book

by Anonim

  • Publisher : Unknown Publisher
  • Release : 1997
  • Pages : 329
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK